News | November 10, 2021
Marksons Pharma PAT slips to Rs 46.28 in Q2FY22
Marksans Pharma has reported consolidated financial results for the period ended September 30, 2021
Marksans Pharma has reported consolidated financial results for the period ended September 30, 2021
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
Thermo Fisher Scientific expands diagnostics portfolio to support full qPCR assay development and testing workflow
Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22
The Board of Directors of Wockhardt have approved the unaudited consolidated financial results for the period ended September 30, 2021.
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).
The Lucent 3D Lumbar Interbody System features a functionally unique multi-component device manufactured in a 3D printing sequence
The Board of Directors of Aurobindo Pharma have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021
The new facility will provide an important boost to vaccine capacity in Africa
Subscribe To Our Newsletter & Stay Updated
